Alaunos Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 Commission File Number: 001-33038 Alaunos Therapeutics, Inc.(Exact name of registrant as specified in its charter) 84-1475642(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 501 E. Las Olas Blvd., Suite 300Fort Lauderdale, FL 33301(346) 355-4099(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company andemerging growth company in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 15, 2026 the number of outstanding shares of the registrant's common stock, $0.001 par value, was 2,4422,146 shares. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements as defined in the Private SecuritiesLitigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Quarterly Report thatare not historical fact, and in some cases can be identified by terms such as: “anticipate,” “believe,” “estimate,” “expect,”“forecast,” “intend,” “may,” “plan,” “project,” “target,” "potential," “will” and other words and terms of similar meaning. These statements are based on management’s current beliefs and assumptions and on information currently available tomanagement. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity,performance or achievements to be materially different from the information expressed or implied by these forward-lookingstatements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution youthat these statements are based on a combination of facts and factors currently known by us and our projections of the future, aboutwhich we cannot be certain. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about: •our ability to raise substantial additional capital to continue as a going concern and fund our planned operations;•our ability to successfully advance our preclinical Obesity and Metabolic Disorders Program, including ALN1003,through additional studies, formulation optimization, and manufacturing scale-up for progressing toward IND-enablingactivities;•our ability to enter into partnerships, collaborations or licensing arrangements to support development of our Obesityand Metabolic Disorders Program;•estimates regarding our expenses, use of cash, cash runway, timing of future cash needs and anticipated capitalrequirements;•our ability to license additional intellectual property to support our Obesity and Metabolic Disorders Program or out-license our intellectual property;•our legacy TCR-T assets and limited ongoing efforts to monetize remaining intellectual property and to comply withour existing license agreements;•our expectation of developments and projections relating to competition from other pharmaceutical and biotechnologycompanies or our industry;•our plans relating to conducting futurein vitrotesting,in vivostudies, and non-clinical and investigational new drug orIND-enabling activities;•the anticipated amount, timing and accounting of contract liabilities, milestones and other payments under licensing,collaboration or acquisition agreements, research and development costs and other expenses;•our ability to remain listed on the Nasdaq Capital Market,